SMYD2 and ovarian serous carcinoma: Kukita et al. found that SMYD2 expression levels are significantly increased in high-grade serous ovarian carcinoma (HGSOC) clinical tissues, and knockdown of SMYD2 or inhibition of SMYD2 with LLY-507 accelerates apoptotic cell death.